Report 2017

Board of Directors

Our nine-member Board of Directors and six-member Executive Leadership Team comprise broad and global management experience, comprehensive biotech expertise and in-depth knowledge of Novozymes’ business. The members’ competencies combine to ensure expert management of the company.

Jørgen Buhl Rasmussen

Born 1955. Chairman of the Board since 2017. Adjunct Professor at Copenhagen Business School. Member of the Audit Committee and chairman of the Nomination and Remuneration Committee. Member of the Board since 2011. Elected for one year at a time.

Agnete Raaschou Nielsen

Born 1957. Vice Chairman of the Board since 2017. Member of the Audit Committee and of the Nomination and Remuneration Committee. Member of the Board since 2011. Elected for one year at a time.

Lars Green*

Born 1967. Executive Vice President, Business Services and Compliance, Novo Nordisk A/S. Chairman of the Audit Committee. Member of the Board since 2014. Elected for one year at a time.

Kasim Kutay*

Born 1965. CEO, Novo Holdings A/S. Member of the Board since 2017. Elected for one year at a time.

Kim Stratton

Born 1962. Head of International Commercial, Shire International GmbH. Member of the Nomination and Remuneration Committee. Member of the Board since 2017. Elected for one year at a time.

Mathias Uhlén

Born 1954. Professor at the Royal Institute of Technology (Sweden) and at the Technical University of Denmark (DTU). Member of the Board since 2007. Elected for one year at a time.